Each film coated tablet contains: Roxithromycin 150 mg.
Roxithromycin is a semi-synthetic macrolide antibiotic. It is thought to interfere with bacterial protein synthesis. The actions and uses similar to those of Erythromycin but the absorption and bioavailability are different. Roxithromycin is rapidly absorbed from the gastrointestinal tract and its bioavailability is not markedly affected by milk or food.
For treatment of infections susceptible to this drug in respiratory tract, ear, throat, skin and soft tissues.
Adult dose: 1 tablet twice daily, 30 minutes before meals, or as directed by physician.
Should not be administered to patients hypersensitive to Erythromycin.
In severe liver failure, the dosage should be reduced. Use in pregnant and nursing women should be considered. As macrolide antibiotic are excreted in breast milk and cross the placenta, resulting in low fetal plasma concentration, however, problems with Roxithromycin have not been documented.
Impairment of liver tests, exceptionally cholestatic hepatitis.
There have been a number of reports indicating that macrolide antibiotics may be involved in clinically significant interactions with several drugs. These interactions may be due to inhibition of hepatic metabolism by the macrolide. Therefore, Roxithromycin may potentiate the action of Carbamazepine, Cyclosporin, Theophylline and Warfarin.
Store at temperature not more than 30°C.
J01FA06 - roxithromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.
FC tab 150 mg x 10 x 10's.